The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.
It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).
ESMO-MCBS Scores
Number of studies
| 5 | 17 |
|---|---|
| 4 | 86 |
| 3 | 122 |
| 2 | 32 |
| 1 | 19 |
| A | 34 |
|---|---|
| C | 2 |
ESMO-MCBS Scores by tumour type
| Breast Cancer | 28 |
|---|---|
| Central Nervous System Malignancies | 0 |
| Endocrine Tumours | 19 |
| Gastrointestinal Cancers | 46 |
| Genitourinary Cancers | 49 |
| Gynaecological Malignancies | 28 |
| Head and neck cancer | 6 |
| Refractory NTRK fusion–positive cancers | 2 |
| Sarcoma | 10 |
| Skin Cancers | 21 |
| TMB-H solid tumours | 1 |
| Thoracic Malignancies | 65 |
| dMMR/MSI-H solid tumours | 1 |
| Breast Cancer | 6 |
|---|---|
| Central Nervous System Malignancies | 1 |
| Endocrine Tumours | 0 |
| Gastrointestinal Cancers | 15 |
| Genitourinary Cancers | 2 |
| Gynaecological Malignancies | 0 |
| Head and neck cancer | 0 |
| Refractory NTRK fusion–positive cancers | 0 |
| Sarcoma | 2 |
| Skin Cancers | 8 |
| TMB-H solid tumours | 0 |
| Thoracic Malignancies | 2 |
| dMMR/MSI-H solid tumours | 0 |